| Literature DB >> 31540107 |
You-Ying Chen1,2, Lee-Shing Fang3,4, Yu-Hsin Chen5, Bo-Rong Peng6,7,8, Tung-Pin Su9,10, Thanh-Hao Huynh11,12, Feng-Yu Lin13,14, Chiung-Chin Hu15, Nai-Cheng Lin16, Zhi-Hong Wen17, Jih-Jung Chen18, Chieh-Yu Lee19,20, Jin-Wei Wang21, Ping-Jyun Sung22,23,24,25,26.
Abstract
Three new 8-hydroxybriaranes-fragilides R-T (1-3) were obtained from a sea whip gorgonian coral Junceella fragilis. The structures of briaranes 1-3 were elucidated by using spectroscopic methods, including 1D (1H and 13C NMR), 2D (COSY, HSQC, HMBC, and NOESY experiments) NMR studies, and (+)-HRESIMS. Fragilides S and T (2 and 3) are the only briaranes known to possess 8α-hydroxy and 17β-methyl groups, respectively. Briarane 2 exerted an inhibition effect on iNOS release from RAW264.7; a macrophage cell line that originated from a mouse monocyte macrophage, stimulated with lipopolysaccharides.Entities:
Keywords: Junceella fragilis; anti-inflammatory; briarane; fragilide; iNOS
Mesh:
Substances:
Year: 2019 PMID: 31540107 PMCID: PMC6780648 DOI: 10.3390/md17090534
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of fragilides R–T (1–3), 9-O-deacetylumbraculolide A (4), and a picture of the gorgonian coral Junceella fragilis.
1H NMR data for briaranes 1–3.
| Position | 1 a | 2 b | 3 a |
|---|---|---|---|
| 2 | 4.83 d (7.2) c | 5.47 d (9.5) | 6.33 d (10.8) |
| 3α/β | 1.91 ddd (15.6, 7.2, 5.4); 2.96 dd (15.6, 12.6) | 5.67 dd (16.0, 9.5) | 5.78 dd (12.0, 10.8) |
| 4 | 4.18 dd (12.6, 5.4) | 6.72 d (16.0) | 5.96 d (12.0) |
| 6 | 5.64 d (10.2, 1.2) | 5.20 s | 5.12 br s |
| 7 | 5.97 d (10.2) | 4.97 br s | 4.88 d (4.2) |
| 9 | 4.22 dd (5.4, 3.6) | 5.53 s | 5.59 s |
| 10 | 3.20 d (3.6) | 3.47 s | 4.08 s |
| 12α/β | 2.22 m | 2.24 m; 2.38 m | 5.37 dd (5.4, 3.0) |
| 13α/β | 1.96 m; 1.81 m | 1.84 m; 1.74 m | 2.06 m |
| 14 | 4.74 dd (4.2, 1.8) | 4.84 dd (2.5, 2.0) | 4.94 dd (4.2, 3.0) |
| 15 | 1.25 s | 1.18 s | 1.16 s |
| 16a/b | 2.09 d (1.2) | 5.49 s; 5.32 s | 5.66 s; 5.48 s |
| 17 | 3.11 q (7.2) | 2.93 q (7.5) | 2.90 q (7.2) |
| 18 | 1.14 d (7.2) | 1.18 d (7.5) | 1.22 d (7.2) |
| 20a/b | 4.97 s; 4.88 s | 4.93 s; 4.76 s | 5.33 s; 4.72 s |
| OH-8 | - | 3.11 s | 2.70 s |
| OH-9 | 2.09 d (5.4) | - | - |
| Acetoxy groups | 1.94 s | 2.01 s | 2.00 s |
| Propionoxy group | - | - | 1.08 t (7.2) |
| Isovaleroxy group | - | - | 0.96 d (6.6) |
a Spectra measured at 600 MHz in CDCl3. b Spectra measured at 500 MHz in CDCl3. c J values (in Hz) in parentheses.
13C NMR data for briaranes 1–3.
| Position | 1 a | 2 b | 3 a |
|---|---|---|---|
| 1 | 48.2, C c | 47.5, C | 47.7, C |
| 2 | 73.3, CH | 76.9, CH | 70.4, CH |
| 3 | 39.7, CH2 | 129.7, CH | 130.4, CH |
| 4 | 71.4, CH | 135.4, CH | 128.7, CH |
| 5 | 146.9, C | 142.6, C d | 137.5, C |
| 6 | 123.1, CH | 66.0, CH d | 64.5, CH |
| 7 | 76.4, CH | 79.5, CH | 76.9, CH |
| 8 | 83.4, C | 81.8, C | 80.3, C |
| 9 | 74.1, CH | 76.3, CH | 74.8, CH |
| 10 | 43.0, CH | 41.8, CH | 37.0, CH |
| 11 | 152.3, C | 149.3, C | 146.3, C |
| 12 | 29.0, CH2 | 29.1, CH2 | 74.3, CH |
| 13 | 27.8, CH2 | 26.0, CH2 | 31.4, CH2 |
| 14 | 74.2, CH | 74.4, CH | 73.0, CH |
| 15 | 15.6, CH3 | 16.4, CH3 | 14.7, CH3 |
| 16 | 26.2, CH3 | 118.8, CH2 d | 116.4, CH2 |
| 17 | 43.8, CH | 49.3, CH | 50.7, CH |
| 18 | 6.6, CH3 | 9.1, CH3 | 8.7, CH3 |
| 19 | 176.7, C | 174.1, C d | 173.9, C |
| 20 | 111.3, CH2 | 111.4, CH2 | 115.2, CH2 |
| Acetoxy groups | 21.0, CH3 | 21.2, CH3 | 20.7, CH3 |
| Propionoxy group | - | - | 8.8, CH3 |
| Isovaleroxy group | - | - | 22.6, CH3 |
a Spectra measured at 150 MHz in CDCl3. b Spectra measured at 125 MHz in CDCl3. c Multiplicity deduced by DEPT and HSQC spectra. d Chemical shfits were assigned by HSQC or HMBC experiments.
Figure 2The COSY () correlations, selective HMBC (), and selective protons with key NOESY correlations () of 1.
Figure 3The COSY () correlations, selective HMBC (), and selective protons with key NOESY correlations () of 2.
Figure 4The COSY () correlations, selective HMBC (), and selective protons with key NOESY correlations () of 3.
Effects of briaranes 1–3 on LPS-induced pro-inflammatory iNOS and COX-2 protein expression in macrophages.
| Compound | iNOS | COX-2 | β-Actin |
|
|---|---|---|---|---|
| Expression (% of LPS) | ||||
| Negative Control | 1.80 ± 0.21 | 1.04 ± 0.35 | 110.02 ± 5.23 | 2 |
| LPS | 100.01 ± 5.06 | 100.06 ± 0.43 | 100.07 ± 8.4 | 4 |
|
| 104.11 ± 16.63 | 100.51 ± 6.11 | 105.70 ± 7.05 | 4 |
|
| 61.21 ± 9.61 | 100.01 ± 5.11 | 99.29 ± 11.29 | 3 |
|
| 100.91 ± 24.08 | 96.36 ± 21.31 | 115.29 ± 3.4 | 4 |
| Dexamethasone | 5.54 ± 1.72 | 8.15 ± 5.13 | 105.21 ± 15.57 | 4 |
Data were normalized to those of cells treated with LPS alone, and cells treated with dexamethasone were used as a positive control. Data are expressed as the mean ± SEM (n = 2–4).